MCMedicalCodingSoftware
J9191

J9191: Injection, fluorouracil (avyxa), 10 mg

HCPCSActiveBETOS O1D

J9191 is a HCPCS Level II code for injection, fluorouracil (avyxa), 10 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.

The CMS record for J9191

Long descriptor
Injection, fluorouracil (avyxa), 10 mg

The official wording. This is what the code means.

Short descriptor
Inj fluorouracil (avyxa)10mg

CMS's 28-character form, which is what shows up on a remittance advice.

Added
October 1, 2026

When CMS introduced the code.

BETOS
O1D

Berenson-Eggers Type of Service: CMS's own analytic grouping.

Pricing indicator
51: Other

Drugs.

Codes adjacent to J9191

HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If J9191 is not quite right, the correct code is very often within a few positions of it.

  • J9179Injection, eribulin mesylate, 0.1 mg
  • J9181Injection, etoposide, 10 mgterminated
  • J9183Gemcitabine intravesical system, 225 mg
  • J9184Injection, gemcitabine hydrochloride (avyxa), 200 mg
  • J9185Injection, fludarabine phosphate, 50 mg
  • J9186Injection, etoposide (avyxa), 1 mg
  • J9187Injection, etoposide, 1 mg
  • J9190Injection, fluorouracil, 500 mgterminated
  • J9192Injection, fluorouracil, 10 mg
  • J9196Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
  • J9198Injection, gemcitabine hydrochloride, (infugem), 100 mg
  • J9199Injection, gemcitabine hydrochloride (infugem), 200 mgterminated
  • J9200Injection, floxuridine, 500 mg
  • J9201Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
  • J9202Goserelin acetate implant, per 3.6 mg
  • J9203Injection, gemtuzumab ozogamicin, 0.1 mg
HCPCS Level II2026Q4-Oct· effective October 1, 2026